Peter Lynch · Growth at a reasonable price (GARP)
Is ACADIA Pharmaceuticals Inc. (ACAD) a Peter Lynch Stock?
Strong GARP candidate: growth at a reasonable price.
71/100
Mitigé
4/6 critères validés
Les critères de Peter Lynch, appliqués à ACAD
PEG ≤ 1.0
clé-
EPS CAGR ≥ 15%
clé-
Revenue CAGR ≥ 10%
22.0%
Net margin > 0
34.3%
Comment ACAD se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$3.44B
PER (TTM)
9.6x
ROIC (TTM)
6.17%
Marge brute
91.47%
Autres analyses Peter Lynch
Questions fréquentes
What is ACAD's Peter Lynch fit score?
ACAD scores 71/100 on our Peter Lynch fit engine. Strong GARP candidate: growth at a reasonable price.
Does Peter Lynch actually own ACAD?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ACAD.
How often is this score updated?
ACAD's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande ACAD personnellement.
